ACA
CRL icon

AYAL Capital Advisors’s Charles River Laboratories CRL Stock Holding History

AYAL Capital Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-28,300
Closed -$6.69M – 40
2023
Q4 		$6.69M Buy
+28,300
New +$5.57M 2.8% 7

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

AYAL Capital Advisors's CRL Position: Q1 2024 in Review

AYAL Capital Advisors sold out of Charles River Laboratories (CRL) in Q1 2024, closing a stake of 28,300 shares — an estimated $6.69M sold.

AYAL Capital Advisors first reported a position in CRL in Q4 2023 and held it in 1 quarter. The position peaked at $6.69M in Q4 2023. 676 funds tracked by Wall St. Rank hold CRL as of Q1 2024.

  • AYAL Capital Advisors reported no remaining Charles River Laboratories position as of Q1 2024 after selling out during the quarter.
  • AYAL Capital Advisors sold 28,300 Charles River Laboratories shares in Q1 2024, an estimated $6.69M.
  • AYAL Capital Advisors first reported a position in Charles River Laboratories in Q4 2023 and held it in 1 quarter.
  • AYAL Capital Advisors's Charles River Laboratories position peaked at $6.69M in Q4 2023.
  • 676 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2024.

Based on AYAL Capital Advisors's 13F filing for Q1 2024, filed 15 May 2024.